the host, and provides protective efficacy after a single dose. This technology is available for licensing, as a biological material, for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

**Potential Commercial Applications**
- Single dose vaccine against COVID–19

**Competitive Advantages**
- Utilizes the established and well-characterized VSV–EBOV vector
- Expresses high antigen titers within host cells
- Single dose protective efficacy against COVID–19
- Inexpensive and replicable

**Development Stage**
- Prototype
- In vivo/In vitro

**Inventors:** Andrea Marzi (NIAID), Wakako Asada (NIAID). **Licensing Contact:** To license this technology, please contact Jeffrey Thruston at 301–594–5179 or jeffrey.thruston@nih.gov, and reference E–233–2017–0.


Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2021–02294 Filed 2–3–21; 8:45 am]

**BILLING CODE 4140–01–P**

---

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting:

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Library of Medicine; Special Emphasis Panel; K99 and K23 Awards (DP2 Clinical Trial Not Allowed). **Date:** March 2–3, 2021. **Time:** 10:00 a.m. to 6:00 p.m. **Agenda:** To review and evaluate grant applications. **Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F52, Rockville, MD 20892 (Virtual Meeting).

**Contact Person:** Jennifer H. Meyers, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F52, Rockville, MD 20852, 301–761–6602, jennifer.meyers@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 26, 2021.

Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–02276 Filed 2–3–21; 8:45 am]

**BILLING CODE 4140–01–P**